Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

446

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

October 31, 2005

Study Completion Date

October 31, 2006

Conditions
AnemiaKidney Disease
Interventions
DRUG

Darbepoetin Alfa

Initial dose, frequency and route of administration of study drug will be the same as that administered for darbepoetin alfa prior to enrollment. Frequency either once a week or once every two weeks, frequency may not change for duration of study. Route of administration either subcutaneous or intravenous, route of administration may not change for duration of study. Study drug provided in pre-filled syringes at the following unit doses: 10, 15, 20, 30, 40, 50, 60, 80, 100 or 150 ug.

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY